Clinical Trials Logo

Appendix Adenocarcinoma clinical trials

View clinical trials related to Appendix Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05734430 Recruiting - Appendix Cancer Clinical Trials

Genetics of Appendix Cancer Study

GAP
Start date: November 11, 2022
Phase:
Study type: Observational

The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individuals diagnosed with appendix/appendiceal cancer who are ages 18+ years.

NCT ID: NCT03108131 Completed - Clinical trials for Locally Advanced Malignant Neoplasm

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.

NCT ID: NCT03074513 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.